PAMP
NRIX icon

Polar Asset Management Partners’s Nurix Therapeutics NRIX Stock Holding History

Polar Asset Management Partners’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-154,400
Closed -$1.76M – 770
2025
Q2 		$1.76M Buy
+154,400
New +$1.67M 0.03% 322
2024
Q4 		– Sell
-27,000
Closed -$607K – 759
2024
Q3 		$607K Buy
+27,000
New +$612K 0.01% 447

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Asset Management Partners's NRIX Position: Q3 2025 in Review

Polar Asset Management Partners sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 154,400 shares — an estimated $1.76M sold.

Polar Asset Management Partners first reported a position in NRIX in Q3 2024 and held it in 2 quarters. The position peaked at $1.76M in Q2 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Polar Asset Management Partners reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Polar Asset Management Partners sold 154,400 Nurix Therapeutics shares in Q3 2025, an estimated $1.76M.
  • Polar Asset Management Partners first reported a position in Nurix Therapeutics in Q3 2024 and held it in 2 quarters.
  • Polar Asset Management Partners's Nurix Therapeutics position peaked at $1.76M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.